LRMR Larimar Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LRMR

Price (delayed)

$3.27

Market cap

$143.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$108.9M

Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical ...

Highlights
The EPS has soared by 67% YoY and by 21% from the previous quarter
LRMR's quick ratio is up by 10% year-on-year
The debt has grown by 6% from the previous quarter but it has contracted by 3.1% YoY
The company's net income rose by 4.8% YoY but it fell by 2.3% QoQ
LRMR's equity is down by 22% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://larimartx.com
Peers: OMGA

Key stats

What are the main financial stats of LRMR
Market
Shares outstanding
43.91M
Market cap
$143.57M
Enterprise value
$108.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$33.38M
EBITDA
-$33.18M
Free cash flow
-$30.79M
Per share
EPS
-$0.6
Free cash flow per share
-$0.7
Book value per share
$2.14
Revenue per share
$0
TBVPS
$2.37
Balance sheet
Total assets
$103.95M
Total liabilities
$11.24M
Debt
$5.39M
Equity
$92.71M
Working capital
$91.92M
Liquidity
Debt to equity
0.06
Current ratio
15.02
Quick ratio
14.78
Net debt/EBITDA
1.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-29%
Return on equity
-32.6%
Return on invested capital
-77.3%
Return on capital employed
-34.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LRMR stock price

How has the Larimar Therapeutics stock price performed over time
Intraday
-3.82%
1 week
-1.51%
1 month
22.93%
1 year
7.21%
YTD
-20.82%
QTD
-17.22%

Financial performance

How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.04M
Net income
-$33.38M
Gross margin
N/A
Net margin
N/A
Larimar Therapeutics's operating income has decreased by 8% YoY and by 5% QoQ
The company's net income rose by 4.8% YoY but it fell by 2.3% QoQ

Growth

What is Larimar Therapeutics's growth rate over time

Valuation

What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
1.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 67% YoY and by 21% from the previous quarter
LRMR's equity is down by 22% year-on-year and by 7% since the previous quarter
LRMR's P/B is 10% below its last 4 quarters average of 1.7 and 4.4% below its 5-year quarterly average of 1.6

Efficiency

How efficient is Larimar Therapeutics business performance
The ROIC has soared by 50% YoY and by 10% from the previous quarter
LRMR's ROE is up by 33% year-on-year but it is down by 9% since the previous quarter
Larimar Therapeutics's ROA has increased by 29% YoY but it has decreased by 9% from the previous quarter

Dividends

What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LRMR.

Financial health

How did Larimar Therapeutics financials performed over time
The total assets is down by 22% YoY and by 7% QoQ
LRMR's total liabilities is down by 22% year-on-year and by 4.6% since the previous quarter
The debt is 94% less than the equity
LRMR's equity is down by 22% year-on-year and by 7% since the previous quarter
LRMR's debt to equity is up by 20% from the previous quarter and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.